Dean, E, Steele, N, Arkenau, H-T, Blackhall, F, Lindsay, C, Saggese, M, Califano, R, Greystoke, A, Voskoboynik, M, Ghiorghiu, D, Dymond, A, Smith, I & Plummer, R 2017, ' SELECT-3: a phase I study of the MEK1/2 inhibitor selumetinib in combination with first-line chemotherapy regimens for NSCLC ', British Journal of Cancer . https://doi.org/10.1038/bjc.2017.271